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Open access under CC BY license.There are more than half a billion cases of malaria every
year. Combinations of an artemisinin with other anti-
malarial drugs are now recommended treatments for
Plasmodium falciparum malaria in most endemic areas.
These treatment regimens act rapidly to relieve symp-
toms and effect cure. There is considerable controversy
on how artemisinins work and over emerging indi-
cations of resistance to this class of antimalarial drugs.
Several individual molecules have been proposed as
targets for artemisinins, in addition to the idea that
artemisinins might have many targets at the same time.
Our suggestion that artemisinins inhibit the parasite-
encoded sarco–endoplasmic reticulum Ca2C-ATPase
(SERCA) PfATP6 has gained support from recent
observations that a polymorphism in the gene encoding
PfATP6 is associated with in vitro resistance to
artemether in field isolates of P. falciparum.
The importance of artemisinins as antimalarials
Artemisinin derivatives (Figure 1) are uniquely important
antimalarial agents. They are useful for treating other-
wise resistant parasites [1] and they act faster and over a
wider range of parasite developmental stages than other
antimalarials [2]. Recently, a study has shown that
artesunate reduces mortality compared with quinine in
the treatment of severe Plasmodium falciparum malaria
[3], although this study has raised some interesting issues
[4,5]. Like quinine, artemisinin is derived from a plant but
is structurally a most distinct compound. The pharmaco-
phore consists of a peroxide within a 1,2,4-trioxane
configuration, the presence of which has led to several
suggestions of how these antimalarials might work [6].
Many of these suggestions have been based on the
understanding of classic peroxide chemistry, and much
of the experimental evidence that has been accumulated is
based on the chemical behaviour of artemisinins [7,8].
However, the application of medicinal chemistry prin-
ciples rather than any prior consideration on how the
peroxide exerts its antimalarial activity has led toCorresponding author: Krishna, S. (s.krishna@sgul.ac.uk).
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and toxicity) and to the successful synthesis of artemisone
[9–12], which is one of the most potent semi-synthetic
derivates that is undergoing clinical studies. Experimen-
tal chemistry has also generated fully synthetic trioxo-
lanes, which are currently being developed for clinical use
[13]. None of these approaches has required knowledge of
the mechanisms of action of these drugs.
Understanding how artemisinins work is currently
particularly important given the accumulating evidence
for artemisinin resistance. The World Health Organization
(WHO) has recently underlined this problem by reinforcing
previous recommendations that artemisinins should only
be used in combination with other antimalarials. Moreover,
the WHO publicly requested pharmaceutical companies to
end the marketing and sale of ‘single-drug’ artemisinin
malaria medicines (monotherapy) to prevent malaria
parasites from developing resistance to this drug (http://
www.who.int/mediacentre/news/releases/2006/pr02/en/
index.html). This call comes at a time when several
observations challenge the notion that artemisinin resist-
ance does not develop. These include: (i) the development of
stable resistance to artemisinin after selection pressure in
an animal model [14]; (ii) the observation of in vitro
resistance to artemether in isolates from French Guiana
[15]; and (iii) the first longitudinal clinical study that
demonstrated a link between reduced in vitro artemisinin
susceptibility and loss of clinical efficacy of artesunate
monotherapy [16].
The advantages of understanding the molecular basis
of drug resistance are evident: monitoring drug resistance
by using molecular techniques avoids the use of more
cumbersome assays that depend purely on phenotypic
observation. In addition, if a mutated target confers
resistance, then it might be possible to design a derivative
that circumvents the effects of the mutation.
Resistance to antimalarial drugs commonly arises from
one of two possible mechanisms: alteration in drug
disposition (usually increased drug efflux from parasites)
or changes in susceptibility of drug targets. Monitoring
genotypic markers of drug resistance might be applied toOpinion TRENDS in Molecular Medicine Vol.12 No.5 May 2006ed.2006.03.005
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Figure 1. Qı¯ng ha¯o su, also known as artemisinin (1) and derivatives. 2,
dihydroartemisinin; 3, artemether; 4, arteether; 5, artesunate. The numbering
scheme is that used by Chemical Abstracts (www.cas.org).
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[20]. The target of dihydrofolate-reductase inhibitors is an
excellent example where identification and structural
resolution of an antimalarial target has helped develop
derivatives to bypass mutations that cause resistance
[21,22]. In contrast, discussion on the mechanism of action
of artemisinins has been mired in detailed yet disparate
hypotheses that suggest that artemisinins have multiple
targets [6,23].
Thus far, the lack of evidence for artemisinin resistance
has supported multiple-target models for the mechanism
of action of artemisinins. Indeed, mutations that reduce
artemisinin affinity would need to occur in all the targets
before resistance would develop (becoming increasingly
improbable as the number of targets increases). Therefore,
the lack of evidence for artemisinin resistance and the
multiple-target theory of artemisinin action have been
self-sustaining by generating wonderfully circular argu-
ments such as: ‘resistance to drugs that have multiple
targets is less likely to develop than resistance to drugs
that have a single target. Therefore, because resistance to
artemisinins has not yet developed, these drugsmust have
multiple targets’. A critical re-evaluation of these inter-
dependent systems will inevitably require assimilation of
data from both field-based studies and basic science. Here,
we will discuss some recent developments that are
relevant to understand the mechanism of action of
artemisinins and put them in the context of previous
mechanistic arguments.Mechanism of action of artemisinins
Progression from chemistry experiments to validation of
the mechanism of action of a drug can be a lengthy
process. For example, to progress from understanding the
metabolism of cholesterol to the use of statins for the
treatment of hyperchloresterolaemia took w40 years
[24,25]. Validation of drug targets (at least in the ‘pre-
omics’ era) can also take years or decades because the
process requires inputs from different disciplines to make
a convincing case that a target is worth hitting. Reverse
pharmaceutics, which identifies the target of validated
drugs, might take an equally long time and not be
always successful.
An endoperoxide bridge is the key pharmacophore in
the semi-synthetic (and synthetic) antimalarial peroxidic
compounds. 1-Carba derivatives of artemisinin are
ineffective in killing parasites [26]. Many other deriva-
tives have been studied for structure–activity relation-
ships against parasites but as yet few systematic studieswww.sciencedirect.comhave been carried out against proposed targets. Work with
enantiomerically pure 1,2,4-trioxanes that have similar
potency has been regarded as evidence against a specific
interaction at an enzyme active site [27]. The implication
is that if protein-chiral recognition is required for this
class of compounds, there should be differences between
antimalarial activities of different enantiomers. This
conclusion implicitly reflects the idea that C-centred
radicals that are generated from endogenous ferrous
iron (either free or within heme) account for the
antimalarial activity of artemisinins [8]. However, this
idea has not been yet adequately tested because of
problems with current approaches. For example, whole-
cell assays such as those performed on parasites in culture
cannot account for differences that are due to differential
partitioning of enantiomers into parasites or other
pharmacodynamic properties that modulate drug potency.
To conduct satisfactory experiments on the relevant
enantiomers requires assays against proposed targets
and, even then, it cannot be assured that enantiomers will
elicit a different response. This depends on the nature and
precision of the binding process that, with respect to the
proposed PfATP6 target (see below), has not yet been
precisely defined.
The unlikelihood of heme as a target
The heme hypothesis arose in conjunction with the
observation that the endoperoxide that is crucial for
antimalarial activity is likely to be ‘activated’ by
Fe2C[28], because heme is a concentrated repository for
Fe2C. This hypothesis has been supported by other
observations that include the targeting of heme by
quinoline antimalarials [29] and the demonstration that
artemisinin can react with heme both in vitro and in an
animal model [30,31].
Although studies in mice have shown that labelled
artemisinin is recovered in a form that is associated with
heme [31], in a Plasmodium vinckei model the Rane test,
which uses a single high dose of antimalarial to cure
infection, was here used intraperitoneally at a dose of
100 mg per kilogram of artemisinin to analyse the fate
of artemisinin in the presence of high parasitaemias
(40–75% infected erythrocytes). In this model, recovery of
heme–artemisinin was!3%. Infected red cells haemolyse
and release haemozoin; therefore, it cannot be assumed
that interactions between artemisinin and heme are
exclusively occurring in the intra-erythrocytic context
rather than after parasite release. Fluorescent artemisi-
nin derivatives that were examined in living parasites
using confocal microscopy do not localize in the parasite
food vacuole that contains heme [32]. These results are
consistent with classic studies that used high-resolution
electron microscopy and radiolabelled artemisinin [33],
where labelling was associated with intraparasitic mem-
brane-bound structures. Others have reported that
tritiated dihydroartemisinin labels the food vacuole, but
close inspection of the relevant images suggests that
labelling is outside food vacuoles of the parasite and not
with heme [34].
Furthermore, these results are consistent with pre-
vious observations that !15% of artemisinin is in
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radiolabelled drug [35], and that parasite stages that lack
visible pigment are killed by artemisinins [2,36]. The
association constants of heme and artemisinins also
indicate low-affinity interaction (KdO10 mM) in in vitro
studies [30]. Moreover, some artemisinin derivatives
maintain antimalarial potency but cannot react with
heme in conventional chemistry models of this interaction
[9,10,37]. Debates over the possibility that such inter-
actions between artemisinin and heme might occur in
different chemical environments highlight the fact that,
just because a particular reaction can occur, it does not
mean that it actually occurs in that crucially important
biological context where drug action takes place.
Are there multiple targets for artemisinin?
The propensity for reactive intermediates formed by
Fe2C-mediated catalysis to alkylate protein targets was
explored some years ago by experiments where several
parasite proteins were labelled with radiolabelled artemi-
sinins [35]. However, the efficiency of labelling was low
and it took several weeks to develop signals of labelled
proteins. Partial micro-sequencing of one of these signals
identified translationally controlled tumour protein
(TCTP) [38], although most of the labelling was observed
in an uncharacterized membrane fraction of the parasites.
Other labelled proteins have yet to be identified. Inter-
action of tritiated dihydroartemisinin with TCTP seems to
be of low affinity (KdO10 mM), as inferred from data
presented in [38].
Possible single targets for artemisinin
Several years ago, P-type ATPases were proposed as new
targets for antimalarials. This suggestion was mainly
based on the fact that selective inhibitors of P-type
ATPases were already clinically used for cardiovascular
and gastrointestinal disorders [39–41]. We indicated that
artemisinins might inhibit the sarco–endoplasmic reticu-
lum Ca2C-ATPase (SERCA) of P. falciparum (PfATP6)
and, therefore, also SERCAs of other Plasmodium species
because thapsigargin is a potent and selective inhibitor of
SERCAs and it shares some chemical similarities with
artemisinins [32]. This suggestion was substantiated by
several independent experimental approaches. Artemisi-
nins, but not other antimalarial drugs, inhibited PfATP6
activity when PfATP6 was expressed and assayed in
Xenopus oocytes [32]. There was an excellent correlation
(R2O0.9) between inhibitory constants of artemisinins
that were assayed in the oocyte model of PfATP6 and the
effectiveness of artemisinins as antimalarials that were
assayed in parasite cultures. 1-Deoxyartemisinin did not
inhibit PfATP6 in oocyte preparations, or kill parasites
in culture unless it was used at very high concentrations
(O10 mM) [32]. Artemisinin has a similar distribution
compared with thapsigargin in studies on living parasites.
Appropriate cross-competition studies using thapsigargin
and artemisinins demonstrated that these drugs antagon-
ise each other when they are assayed in parasite
cultures [32].
Others have carried out docking simulation studies of
artemisinin derivatives to models of the thapsigarginwww.sciencedirect.combinding site in PfATP6 [42]. Several potential hydrophobic
interactions between side chains of artemisinin deriva-
tives and amino acids of PfATP6 have been identified
including Leu263 (which is potentially interacting with
side chain at C-12 b-position [42]). Leu263 modulated
artemisinin susceptibility when examined using muta-
genesis experiments of malarial SERCAs [12]. Taken
together, there are independent lines of evidence that
have been obtained from a range of experimental
techniques to suggest that PfATP6 might be the primary
target of artemisinins. However, it is suggested that
genetic studies are required to support this hypothesis.
More recently, others have suggested that the electron
transport chain of P. falciparum might be a target for
artemisinins [43]. In support of this idea, when yeast was
grown in non-fermentable media (making it dependent on
mitochondrial respiration), sensitivity to artemisinin
increased by several orders of magnitude (with IC50
values decreasing from 80 mM to w10 nM). This was
accompanied by a reduction in rhodamine uptake into
mitochondria. Deletion mutants nde1D and ndi1D, both of
which lack the yeast NADH dehydrogenases NDE1 and
NDE2, were relatively resistant to artemisinin and grew
on fermentable media that contain 4 mM artemisinin [43].
Interestingly, overexpression of NDE1 and NDE2 (over-
expression is inferred because they are under the
regulation of an ADH1 promoter) made engineered yeast
more sensitive to artemisinins than wild-type yeast.
Substitution of the P. falciparum orthologue (PfND1I)
partially restored sensitivity to artemisinins, although
this effect has not yet been quantified precisely [43].
Because overexpression of some mitochondrial-transport
proteins seems to increase sensitivity to artemisinins
(which is contrary to what would be expected if these were
targets of artemisinins because sensitivity would
decrease), it has been suggested that the electron
transport chain stimulates the activity of artemisinins,
and that these activated artemisinins impede mitochon-
drial function by depolarizing mitochondrial membrane
potential [43].
It is well known that artemisinin and its first-
generation derivatives affect the mitochondrial inner
membrane potential in neuronal-cell cultures, where
interference of electron transport associated with the
respiratory chain is implicated [44]. Inhibition of the inner
membrane potential by artemisinins has also been
described in parasites [45], where it has been shown that
the respiratory chain of Plasmodium parasites is similar
to that of mammals with regard to classic mitochondrial
inhibitors of complex I–IV [45]. Artemisinin and prima-
quine inhibited the respiratory chain of the sexual and
asexual stages of parasites [45]. The mechanism of this
inhibition is unclear but it might be related to the presence
of an iron group in the cytochrome center that induces the
formation of radicals that seem to be unrelated to the anti-
parasitic mode of action. In contrast to first generation
artemisinins, artemisone has been shown to be non-
neurotoxic in screens that were identical to those used to
establish neurotoxicity of artemisinin and related deriva-
tives, supporting the view that artemisone does not affect
mitochondrial inner membrane potential [11].
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that are related to the proposed mechanism of action of
artemisinins as antimalarial drugs? Parasites are incap-
able of aerobic glycolysis during asexual stages and there
is no reported localisation of artemisinins inmitochondria.
Only artemisinin itself has been tested; indeed, the
pharmacophore that is crucial for antimalarial activities
of artemisinins (the endoperoxide bridge) has not yet been
examined by looking at the properties of 1-deoxyartemi-
sinin. It is therefore not easy to relate findings in the yeast
model to activities in parasites.
PfATP6 as target for artemisinins: genetic evidence
In field studies of several hundred isolates that have been
collected from patients with P. falciparum malaria since
1997, the IC50 of artemether of some isolates in French
Guiana was greatly increased (equivalent to reduced
susceptibility to this drug) when they were tested
in vitro after short-term culture [15]. In these isolates,
the IC50 of artemether was unrelated to the IC50 of other
antimalarials. Sequencing of pfATP6 identified an S769N
substitution associated with this elevation in the IC50
value for artemether. Artemether is the only artemisinin
derivative that is included in the currently registered
fixed-dose artemisinin-combination therapy rec-
ommended by WHO (artemether–lumefantrine, also
known as Riamete), although other non-fixed-dose
combination therapies are supposed for use. The median
[interquartile (IQR)] IC50 value for artemether for
parasites with an S769N substitution in pfATP6 was
79.4 nM (37.2–109.3 nM), which is O20-fold higher than
the upper limit of the IQR value for all parasites that have
been studied in French Guiana [median (IQR) Z1.7 nM
(0.98–3.6 nM)]. Interestingly and worryingly, the isolates
that had an increased IC50 value for artemether and an
S769N substitution in pfATP6 originated from areas in
French Guiana that are separated by some distance by
inhabited primary forest. These isolates were collected
several months apart and presented distinct susceptibility
profiles to a range of antimalarials. This clearly indicates
that they were unrelated and, thus, that independent
events were being studied. Isolates from unrelated
patients examined on the same day did not exhibit an
elevation in the IC50 value for artemether, indicating that
the observed increase of IC50 is unlikely to be due to
experimental-culture artefacts. IC50 assays and molecular
studies were carried out independently and molecular
data were generated without knowledge of the in vitro
susceptibility profiles.
An argument that is raised against the notion that
there is no artemisinin resistance is: why has resistance
not arisen in areas where artemisinins have been used
more heavily than in places such as French Guiana? The
examples of resistance to chloroquine and sulfadoxine–
pyrimethamine are helpful because, despite excessive use
of these drugs and, therefore, high selection pressure in
high transmission areas of sub-Saharan Africa, resistance
to these drugs arose first in Southeast Asia and South
America and in few other locations where population
structure and transmission conditions favoured resistance
[46,47,48]. Furthermore, it is not only a question of howwww.sciencedirect.commuch drug is used in a given area but also whether the
drug is appropriately administered and used (e.g. given in
combination with other classes of antimalarial drugs). On
the Thai–Myanmar border and in Cambodia, artemisinin
therapy has been given in combination with mefloquine
[49]. Artemisinin resistance has not been reported in
this area and no genotype–phenotype relationship has
been observed for PfATP6 [50]. However, there is a
risk that, if resistance to the companion drug (e.g.
mefloquine) increases, this will leave artemisinins acting
as monotherapies.
Antimalarial-drug pressure has been exerted on
parasites in French Guiana and in surrounding areas
such as Surinam and Brazil; parasites in these areas are
currently resistant to several antimalarials and have
mutations in many of the genes associated with multi-
drug resistance. These parasites have a typical South-
American genetic background that differs in many drug-
resistance alleles when compared with those in Southeast
Asia and Africa [15].
This genetic makeup might sustain viability of para-
sites that carry mutations in pfATP6 (overcoming the
‘fitness cost’ of these mutations [51]) and might explain
why elevations in the IC50 of artemether have been
observed in French Guiana. The inappropriate local use
of illegally imported antimalarials that act in the genetic
background of these parasites might have catalysed the
emergence of drug resistance. This also might explain why
adaptation to culture of these artemether-resistant
isolates has proved challenging so far.
There has been no association between S769N pfATP6
polymorphism and susceptibility to antimalarials such as
mefloquine and chloroquine. Lack of associated poly-
morphisms to TCTP in this geographic area [15] should
prompt re-evaluation of the importance of alkylation
products associated with artemisinins in cultured para-
sites as possible targets. There is a risk that they might be
‘red herrings’ rather than informative for the mechanism
of action.
The data presented by Jambou et al. [15] can be
explained either by the altered affinity of S769N pfATP6
for artemisinins, which directly accounts for the observed
increases in the IC50 value, or by the fact that the altered
affinity of S769N pfATP6 for artemisinins is now so low
that an alternative, lower affinity target(s) becomes
biologically important. Testing the effects of this single
amino acid substitution on susceptibility of pfATP6 to
artemisinins might help resolve this issue. Although the
S769N substitution is located at a site of pfATP6 that is
not predicted to be associated with thapsigargin binding,
it does not diminish its possible relevance to the elevation
of the IC50 for artemisinins. In conformationally active
enzymes, there are many different ways in which binding
to substrates and inhibitors might be influenced by
mutations that are distant to possible binding sites. In
addition, the structural predictions that were made for
PfATP6 are still uncertain; this enzyme has two insertions
that are large compared with those in the mammalian
orthologue, the crystal structure of which has been
established, and that is also insensitive to artemisinins.
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In addition to mutations in pfATP6, other genes might
modulate susceptibility to artemisinins, and these
alternative mechanismsmight be important. For example,
increases in the copy number of P. falciparum multidrug
resistance gene (pfmdr1) modulate susceptibility not only
to chemically unrelated mefloquine (within a clinically
relevant range of IC50 values) but also to artemisinins
(within a small range of IC50 values; for example,w2-fold
change in IC50 values in parasites that have been studied
in Thailand) [50]. Interestingly, there were no differences
in pfmdr1 single nucleotide polymorphisms (SNPs) in
isolates that were susceptible or resistant to artemether in
French Guiana. The relevance of these observations to the
emerging evidence of artemisinin resistance in field
isolates will need to be examined further.
Animal models have also generated stable artemisinin
resistance. For example, selection of genetically stable
resistance to artemisinins in a model of Plasmodium
chabaudi showed that resistance is maintained even after
mosquito passage [14]. Although Afonso et al. [14] did not
identify associated changes (either in sequence or copy
number) in the SERCA orthologue of P. chabaudi or any
other suggested marker of drug resistance in P. falci-
parum (including pfmdr1 and pftctp orthologues), stable
resistance to artemisinins was confirmed. These results
also highlight the difficulties in translating findings from
laboratory models to the study of antimalarial-drug
resistance that is observed in field isolates. It might be
that intrinsically less susceptible SERCAs, such as those
of rodent Plasmodium species [12], make the emergence
of alternative mechanisms for artemisinin resistance
more probable and less relevant to those of P. falciparum.
For example, a hitherto unidentified transporter that
exports artemisinins might be more active in these
resistant strains, and, therefore, reduce the likelihood
of selection for more artemisinin-resistant variants of
rodent SERCAs.
Implications for artemisinin resistance
Although decreased susceptibility to an antimalarial drug
in vitro does not necessarily mean therapeutic failure, it
can be stated that, when clinical resistance is documented,
then in vitro susceptibility is also decreased. The temporal
scenario for the establishment of clinically relevant drug
resistance might first include a decrease in in vitro
susceptibility associated with a key mutation in the target
enzyme, followed by accumulation of additional
mutations, ultimately resulting in high rates of clinical
failure [48]. In this way, field observations from French
Guiana might represent the first element of this cascade.
These are still early days for the use of artemisinin-
containing therapies; therefore, there is opportunity to
assess the potential emergence of clinically significant
resistance, and perhaps to try and minimise this risk. The
clinical significance of decreased in vitro susceptibility to
artemisinins needs to be explored further, although there
is a possibility that, once detected, the dissemination of
artemisinin-resistant parasites might be too fast to be
stemmed. There have been few studies that examined the
relationship between in vitro artemisinin susceptibilitywww.sciencedirect.comand treatment response, particularly when artemisinin-
based monotherapy is employed. An interesting study
from Central Africa in non-immune individuals showed
that, after seven days of artesunate monotherapy [52],
parasitological cure rates were 85% at day 42 of follow up
(nZ55 patients. In these patients, PCR-correction was
used to confirm recrudescence rather than re-infection).
Although the IC50 value of dihydroartemisinin was
similar in recrudescent and cured parasites, IC90 values
were 5-fold higher in the recrudescent group (nZ5 out of 8
patients for whom data were obtained) compared with the
non-recrudescent group (nZ17 out of 47; PZ0.02). This
indicates that IC50 measurements might be a less
sensitive marker of in vitro artemisinin resistance than
IC90 measurements. These findings suggest that parasites
with greatly increased inhibitory-constant values for
artemisinins might also be more likely to relapse if
artemisinin-based monotherapy is used to treat
malaria [15].
This emphasizes further the need to use artemisinins in
combination therapies where they act rapidly to reduce
parasite numbers [1,53] rather than mediate final cure.
Combining artemisinins with other antimalarials might
be useful in delaying the emergence of artemisinin
resistance [1], but only if parasites have not developed
high-grade resistance to the companion drug [54].
Although combination therapies have provided sustained
efficacy in some parts of Southeast Asia (O90% cure rates
in Thailand with mefloquine–artesunate combinations
[49]), there are suggestions that in other areas such as
Cambodia the cure rate can fall to !80% (e.g. after
artemether–lumefantrine treatment) [55]. The import-
ance of artemisinin-combination therapy in reducing the
emergence of drug-resistant parasites also needs to be
explored further in areas of high endemicity of malaria. In
any case, it is essential that development of new regimens
is accompanied by monitoring for resistance to each drug
partner using the most sensitive (often genetic) markers
that are available. In this regard, recent advances in the
understanding of resistance mechanisms for artemisinins
and other drugs have come at a fortunate time [15,50].
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